Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 440

1.

Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.

Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C.

Biol Psychiatry. 2010 Apr 15;67(8):715-21. doi: 10.1016/j.biopsych.2010.01.016. Epub 2010 Mar 6.

PMID:
20207347
[PubMed - indexed for MEDLINE]
2.
3.

Brain activity and emotional processing in smokers treated with varenicline.

Loughead J, Ray R, Wileyto EP, Ruparel K, O'Donnell GP, Senecal N, Siegel S, Gur RC, Lerman C.

Addict Biol. 2013 Jul;18(4):732-8. doi: 10.1111/j.1369-1600.2011.00324.x. Epub 2011 Apr 20.

PMID:
21507156
[PubMed - indexed for MEDLINE]
4.

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, Williams KE.

Clin Ther. 2007 Jun;29(6):1027-39.

PMID:
17692719
[PubMed - indexed for MEDLINE]
5.

Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.

Tonstad S.

J Cardiovasc Nurs. 2006 Nov-Dec;21(6):433-6.

PMID:
17293731
[PubMed - indexed for MEDLINE]
6.

Varenicline improves mood and cognition during smoking abstinence.

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.

Biol Psychiatry. 2009 Jan 15;65(2):144-9. doi: 10.1016/j.biopsych.2008.08.028. Epub 2008 Oct 8.

PMID:
18842256
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.

Atzori G, Lemmonds CA, Kotler ML, Durcan MJ, Boyle J.

J Clin Psychopharmacol. 2008 Dec;28(6):667-74. doi: 10.1097/JCP.0b013e31818c9bb8.

PMID:
19011436
[PubMed - indexed for MEDLINE]
8.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
[PubMed - indexed for MEDLINE]
9.

Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study.

Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN, Gur RC, Loughead J, Lerman C.

Drug Alcohol Depend. 2013 Dec 15;133(3):852-6. doi: 10.1016/j.drugalcdep.2013.09.003. Epub 2013 Sep 14.

PMID:
24095246
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR.

Arch Intern Med. 2006 Aug 14-28;166(15):1561-8.

PMID:
16908788
[PubMed - indexed for MEDLINE]
11.

Down-regulation of amygdala and insula functional circuits by varenicline and nicotine in abstinent cigarette smokers.

Sutherland MT, Carroll AJ, Salmeron BJ, Ross TJ, Hong LE, Stein EA.

Biol Psychiatry. 2013 Oct 1;74(7):538-46. doi: 10.1016/j.biopsych.2013.01.035. Epub 2013 Mar 15.

PMID:
23506999
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.

West R, Baker CL, Cappelleri JC, Bushmakin AG.

Psychopharmacology (Berl). 2008 Apr;197(3):371-7. Epub 2007 Dec 15.

PMID:
18084743
[PubMed - indexed for MEDLINE]
13.

Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.

Lam S, Patel PN.

Cardiol Rev. 2007 May-Jun;15(3):154-61. Review.

PMID:
17438382
[PubMed - indexed for MEDLINE]
14.

Effects of varenicline on smoking cue–triggered neural and craving responses.

Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR.

Arch Gen Psychiatry. 2011 May;68(5):516-26. doi: 10.1001/archgenpsychiatry.2010.190. Epub 2011 Jan 3.

PMID:
21199958
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Ashare RL, McKee SA.

Exp Clin Psychopharmacol. 2012 Feb;20(1):63-70. doi: 10.1037/a0025594. Epub 2011 Sep 26.

PMID:
21942262
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Varenicline for smoking cessation: a placebo-controlled, randomized study.

Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S.

Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20.

PMID:
19192221
[PubMed - indexed for MEDLINE]
17.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
[PubMed - indexed for MEDLINE]
18.

Working memory deficits predict short-term smoking resumption following brief abstinence.

Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, Frey J, Gur R, Lerman C.

Drug Alcohol Depend. 2010 Jan 1;106(1):61-4. doi: 10.1016/j.drugalcdep.2009.07.020. Epub 2009 Sep 5.

PMID:
19733449
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT.

J Med Chem. 2005 May 19;48(10):3474-7.

PMID:
15887955
[PubMed - indexed for MEDLINE]
20.

Varenicline: a novel pharmacotherapy for smoking cessation.

Jiménez-Ruiz C, Berlin I, Hering T.

Drugs. 2009 Jul 9;69(10):1319-38. doi: 10.2165/00003495-200969100-00003. Review.

PMID:
19583451
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk